Celularity (CELUW) Share-based Compensation (2020 - 2025)
Celularity (CELUW) reported Share-based Compensation of $9.6 million for Q4 2025, up 226.08% year-over-year from $2.9 million in Q4 2024, and up 1936.09% quarter-over-quarter from $471000.0 in Q3 2025.
Celularity (CELUW) Share-based Compensation (2020 - 2025) Analysis & Trends
Celularity (CELUW) has 6 years of Share-based Compensation data on file, last reported at $9.6 million in Q4 2025.
- Share-based Compensation for Q4 2025 came in at $9.6 million, up 226.08% year-over-year; the trailing twelve-month figure through Dec 2025 was $12.8 million (up 10.69% YoY), and the FY2025 annual result was $10.4 million, down 10.29% from the prior year.
- Share-based Compensation climbed to $9.6 million in Q4 2025 per CELUW's latest filing, from $471000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $28.2 million in Q2 2021 and troughed at -$11.4 million in Q4 2023.
- A 5-year average of $4.0 million and a median of $3.0 million in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation slumped 360.88% in 2023, then surged 226.08% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $1.9 million in 2021, then surged by 126.9% to $4.4 million in 2022, then tumbled by 360.88% to -$11.4 million in 2023, then jumped by 125.7% to $2.9 million in 2024, then surged by 226.08% to $9.6 million in 2025.
- Business Quant data shows CELUW's Share-based Compensation at $9.6 million in Q4 2025, $471000.0 in Q3 2025, and $108000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Celularity | - | - | -3.27 Mn | 9.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.59 Mn |
| Dec 31, 2025 | 9.59 Mn |
| Sep 30, 2025 | 471,000.00 |
| Sep 30, 2025 | 471,000.00 |
| Jun 30, 2025 | 108,000.00 |
| Jun 30, 2025 | 108,000.00 |
| Mar 31, 2025 | 2.64 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Dec 31, 2024 | 2.94 Mn |
| Dec 31, 2024 | 2.94 Mn |
| Sep 30, 2024 | 2.67 Mn |
| Sep 30, 2024 | 2.67 Mn |
| Jun 30, 2024 | 2.99 Mn |
| Jun 30, 2024 | 2.99 Mn |
| Mar 31, 2024 | 2.97 Mn |
| Mar 31, 2024 | 2.97 Mn |
| Dec 31, 2023 | -11.44 Mn |
| Dec 31, 2023 | -11.44 Mn |
| Jun 30, 2023 | 3.86 Mn |
| Jun 30, 2023 | 3.86 Mn |